TC246

PK/PD modeling for anti-Shigella drug candidates

...

Principal Investigator (PI)

...

Project location

the sponsor

Home Institution

University of Washington

Go to PI affiliation web
foundation funding

Foundation funding

The Foundation is providing £199,874.000 in support.

Open Labs Fellow/s

Dr. Samuel Arnold

Project Participant/s

McCloskey - Samuel Arnold

GSK’s contribution

GSK will contribute with its scientific expertise including DMPK support on lead drug candidates and access to PBPK/PD modeling resources.

Project Description

Publications 2

Scientific reports, 9(1)

Evaluation of in vitro and in vivo antibiotic efficacy against a novel bioluminescent Shigella flexneri

McCloskey, M. C., Shaheen, S., Rabago, L., Hulverson, M. A., Choi, R., Barrett, L. K., & Arnold, S. L. M.

Read publication
ACS infectious diseases, 7(5)

Target Product Profile and Development Path for Shigellosis Treatment with Antibacterials

Arnold S. L. M.

Read publication